Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism
Developmental Neurobiology · 2025
DOI: 10.1002/dneu.22955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Neurobiology, 2025. Verfasst von Maiara de Aguiar da Costa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Autism and Neurodevelopmental Research, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, S…. Hauptthemen laut MEDLINE: Cannabidiol, Disease Models, Animal, Rats, Wistar, Risperidone. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Autism spectrum disorder (ASD) is characterized by deficits in communication, social interaction, and repetitive and stereotyped behaviors, with no specific drug therapy available. Studies have found that cannabidiol (CBD) can improve hyperactive and cognitive symptoms in children with ASD. However, little is known about the effect of CBD in combination with other medications, such as risperidone (RISP). This study aimed to evaluate the behavioral and biochemical effects of CBD in animals using a valproic acid (VPA)‐induced ASD animal model. VPA was administered in pregnant Wistar rats on Day 12.5 of gestation to induce the ASD model. From the 10th to the 16th postnatal day (PND), the neurodevelopment of the animals was assessed through eye‐opening, olfactory discrimination, and negative geotaxis behavioral tests. From PNDs 9 to 54, the animals were weighed. They were treated for 21 days with CBD alone (100 mg/kg, by gavage, twice a day) or in combination with RISP (0.1 mg/kg, by gavage, once a day). At PND 55, the animals were evaluated in social interaction and locomotor activity experiments. Finally, after behavioral assessment, the animals were euthanized, the brain was isolated, and oxidative stress parameters were evaluated in the hippocampus and cortex posterior. Animals exposed to VPA showed neurodevelopmental delays in opening their eyes, difficulties in turning around their axis, and took longer time to find the original nest when compared to control animals. They also exhibited impaired sociability and reduced exploratory activity, which indicates model impairments. Interestingly, animals exposed to VPA treated with CBD + RISP significantly improved sociability parameters, whereas isolated CBD did not affect this parameter. In the biochemical analysis, a significant decrease in the hippocampal sulfhydryl content was noted in the CT + CBD group and an increase in the VPA + CBD group. In conclusion, these results suggest that CBD, in combination with RISP, may be an interesting pharmacological approach to reducing ASD‐related symptoms. Summary : Besides the increased prevalence of ASD cases in recent years, there are no medications to improve the central symptoms of autism. Numerous studies discuss CBD as an important medication for improving ASD symptoms; however, it is not known how CBD interacts with commonly used drugs in ASD individuals, such as RISP. This study demonstrated that CBD therapy, only when combined with RISP, improved sociability in a VPA‐induced ASD animal model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Autism and Neurodevelopmental Research, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, Santa Catarina, Brazil.
- Laboratory of Behavioral Neuroscience, Graduate Program in Health Sciences, University of South Santa Catarina (UNISUL), Tubarão, Santa Catarina, Brazil.
ORCID-Profile: Cinara Ludvig Gonçalves
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Costa, M. A. D., Fernandes, G. Z., Maiochi, E., Ebs, M. F. P., Darós, F. D. S., Bolan, S. J., Costa, R. R. N., de Rezende, V. L., da Silva, G. C., Bitencourt, R. M., & Gonçalves, C. L. (2025). Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism. Developmental Neurobiology. https://doi.org/10.1002/dneu.22955
Vancouver
Costa MAD, Fernandes GZ, Maiochi E, Ebs MFP, Darós FDS, Bolan SJ, et al. Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism. Developmental Neurobiology. 2025. doi:10.1002/dneu.22955
BibTeX
@article{Costa2025,
author = {Costa, Maiara de Aguiar da and Fernandes, Gustavo Zanette and Maiochi, Eduarda and Ebs, Maria Fernanda Pedro and Darós, Flávia da Silva and Bolan, Sofia Januário and Costa, Rosiane Ronchi Nascimento and de Rezende, Victória Linden and da Silva, Gláucia Crispim and Bitencourt, Rafael Mariano and Gonçalves, Cinara Ludvig},
title = {Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism},
journal = {Developmental Neurobiology},
year = {2025},
doi = {10.1002/dneu.22955}
}
EUVIMED